These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 32960958)

  • 1. Martinez-Lopez J, Wong SW, Shah N, et al. Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma. Blood Adv. 2020;4(14):3295-3301.
    Blood Adv; 2020 Sep; 4(18):4573. PubMed ID: 32960958
    [No Abstract]   [Full Text] [Related]  

  • 2. Down to the bitter end.
    Lonial S; Gleason C
    Blood; 2014 May; 123(20):3061-2. PubMed ID: 24832937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma.
    Martinez-Lopez J; Wong SW; Shah N; Bahri N; Zhou K; Sheng Y; Huang CY; Martin T; Wolf J
    Blood Adv; 2020 Jul; 4(14):3295-3301. PubMed ID: 32706892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erratum: Reina-Castillón J, Pujol R, López-Sánchez M, et al. Detectable clonal mosaicism in blood as a biomarker of cancer risk in Fanconi anemia.
    Blood Adv; 2017 Aug; 1(18):1368. PubMed ID: 29297518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coelomycetous
    Valenzuela-Lopez N; Cano-Lira JF; Guarro J; Sutton DA; Wiederhold N; Crous PW; Stchigel AM
    Stud Mycol; 2018 Jun; 90():1-69. PubMed ID: 29255336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methodological considerations for the high sensitivity detection of multiple myeloma measurable residual disease.
    Soh KT; Tario JD; Hahn TE; Hillengass J; McCarthy PL; Wallace PK
    Cytometry B Clin Cytom; 2020 Mar; 98(2):161-173. PubMed ID: 31868315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimistic update bias holds firm: Three tests of robustness following Shah et al.
    Garrett N; Sharot T
    Conscious Cogn; 2017 Apr; 50():12-22. PubMed ID: 27836628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple myeloma and kidney transplantation: the beginning of a new era.
    Van den Bosch I; Sprangers B; Gertz M
    Clin Kidney J; 2019 Apr; 12(2):213-215. PubMed ID: 30976398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Wu V, Moshier E, Leng S, et al. Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling.
    Blood Adv; 2018 Sep; 2(17):2186. PubMed ID: 30171082
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical value of measurable residual disease testing for multiple myeloma and implementation in Japan.
    Takamatsu H
    Int J Hematol; 2020 Apr; 111(4):519-529. PubMed ID: 32034671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measurable residual disease in multiple myeloma and light chain amyloidosis: more than meets the eye.
    Vaxman I; Gertz MA
    Leuk Lymphoma; 2021 Jul; 62(7):1544-1553. PubMed ID: 33508994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First Report of Moldy Core of Sweet Tango Apples from New Zealand Caused by Alternaria arborescens.
    Ali S; Abbasi P; Rehman S; Ellouze W
    Plant Dis; 2021 Mar; ():. PubMed ID: 33761775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maintenance therapy in multiple myeloma.
    Mewawalla P; Chilkulwar A
    Ther Adv Hematol; 2017 Feb; 8(2):71-79. PubMed ID: 28203343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hydroids (Cnidaria, Hydrozoa) from Mauritanian Coral Mounds.
    Gil M; Ramil F; AgÍs JA
    Zootaxa; 2020 Nov; 4878(3):zootaxa.4878.3.2. PubMed ID: 33311142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bødker JS, Brøndum RF, Schmitz A, et al. A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis.
    Blood Adv; 2019 Mar; 3(6):874. PubMed ID: 30885999
    [No Abstract]   [Full Text] [Related]  

  • 16. Cho S-F, Lin L, Xing L, et al. The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models. Blood Adv. 2020;4(17):4195-4207.
    Blood Adv; 2020 Nov; 4(22):5772. PubMed ID: 33227124
    [No Abstract]   [Full Text] [Related]  

  • 17. Jagannath S, Abonour R, Durie BGM, et al. Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM. Blood Adv. 2018;2(13):1608-1615.
    Blood Adv; 2020 Feb; 4(3):444. PubMed ID: 31995155
    [No Abstract]   [Full Text] [Related]  

  • 18. The genus name Ensifer Casida 1982 takes priority over Sinorhizobium Chen et al. 1988, and Sinorhizobium morelense Wang et al. 2002 is a later synonym of Ensifer adhaerens Casida 1982. Is the combination "Sinorhizobium adhaerens" (Casida 1982) Willems et al. 2003 legitimate? Request for an Opinion.
    Young JM
    Int J Syst Evol Microbiol; 2003 Nov; 53(Pt 6):2107-10. PubMed ID: 14657154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erratum.
    Science; 1987 Feb; 235(4789):623f. PubMed ID: 17833610
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.